Abstract
Non-traumatic subarachnoid hemorrhage (SAH) represents about 5 to 6% of the overall incidence of stroke and is associated with high morbidity and mortality. Despite the substantial research and clinical efforts, delayed cerebral ischemia (DCI) is still the major complication after SAH and represents an important factor for severe neurological deficits. Cerebral vasospasm (VSP) has been recognised for a long time as an important underlying pathophysiologic cause of DCI, but it is now clearer that the mechanisms underlying DCI are multifactorial. Among other pathomechanisms proposed, ischemia-producing cortical spreading depolarizations (CSDs) are likely to be involved in DCI development. Understanding the plethora of different pathophysiological derangements after SAH is very important for the development of new therapies, in order to abolish secondary ischemic brain injuries early-on and improve patients’ outcome. In this review, we strive to summarise the mechanisms and therapeutic developments of DCI.
Keywords: Cerebral vasospasm, cortical spreading depolarization, delayed cerebral ischemia, spreading ischemia, subarachnoid hemorrhage, treatment, Spontaneous subarachnoid hemorrhage (SAH), DCI, CSF, CSDs
Current Neurovascular Research
Title:Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Volume: 9 Issue: 4
Author(s): Zelong Zheng, Renan Sanchez-Porras, Edgar Santos, Andreas W. Unterberg and Oliver W. Sakowitz
Affiliation:
Keywords: Cerebral vasospasm, cortical spreading depolarization, delayed cerebral ischemia, spreading ischemia, subarachnoid hemorrhage, treatment, Spontaneous subarachnoid hemorrhage (SAH), DCI, CSF, CSDs
Abstract: Non-traumatic subarachnoid hemorrhage (SAH) represents about 5 to 6% of the overall incidence of stroke and is associated with high morbidity and mortality. Despite the substantial research and clinical efforts, delayed cerebral ischemia (DCI) is still the major complication after SAH and represents an important factor for severe neurological deficits. Cerebral vasospasm (VSP) has been recognised for a long time as an important underlying pathophysiologic cause of DCI, but it is now clearer that the mechanisms underlying DCI are multifactorial. Among other pathomechanisms proposed, ischemia-producing cortical spreading depolarizations (CSDs) are likely to be involved in DCI development. Understanding the plethora of different pathophysiological derangements after SAH is very important for the development of new therapies, in order to abolish secondary ischemic brain injuries early-on and improve patients’ outcome. In this review, we strive to summarise the mechanisms and therapeutic developments of DCI.
Export Options
About this article
Cite this article as:
Zheng Zelong, Sanchez-Porras Renan, Santos Edgar, W. Unterberg Andreas and W. Sakowitz Oliver, Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations, Current Neurovascular Research 2012; 9 (4) . https://dx.doi.org/10.2174/156720212803530663
DOI https://dx.doi.org/10.2174/156720212803530663 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Local Cerebral Blood Flow is Preserved in Sepsis
Current Neurovascular Research Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Acellular Spinal Cord Scaffold Implantation Promotes Vascular Remodeling with Sustained Delivery of VEGF in a Rat Spinal Cord Hemisection Model
Current Neurovascular Research Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Effect of Piperine, Quercetin, Polysorbate 80 on the Oral Bioavailability of Losartan in Male Wistar Rats
Pharmaceutical Nanotechnology Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design